(RTTNews) - Swiss drug major Novartis AG (NVS) announced Monday positive topline results from a pre-specified interim analysis of the Phase III PSMAddition trial for Pluvicto plus hormone therapy in ...
Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. The move comes as Novartis’ second-quarter sales of $14 billion met Wall Street’s ...
Novartis CEO Vas Narasimhan is doubling down on his $5 billion peak sales projection for Pluvicto, even as the company has given up on a label expansion in Europe. Novartis withdrew its European ...
Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...
Novartis already received FDA approval of ITVISMA as a gene therapy for the treatment of patients with SMA. Read why NVS ...
Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA–positive mCRPC who have been treated with androgen-receptor pathway inhibitor ...
The launch comes at a time when prostate cancer cases in India are rising sharply Swiss drugmaker Novartis has introduced Pluvicto in India, marking the country’s first regulatory-approved radioligand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results